Version history

{
  "session_id": "sess_SDA-2026-04-11-gap-debate-20260410-111928-22fc607c",
  "round_number": 1,
  "agent_persona": "persona-theorist",
  "agent_backend": "minimax:MiniMax-M2.7",
  "action": "propose",
  "content": "\n\n# Therapeutic Hypotheses: Safe TREM2 Receptor Modulation Reversal Without Tolerance or Rebound Inflammation\n\n## Hypothesis 1: β-Arrestin Biased agonism to Prevent Classical Desensitization\n\n**Description**: TREM2 signals through SYK and PLCγ2, but receptor phosphorylation by GRKs recruits β-arrestin 2, which can either scaffold active signaling complexes or trigger receptor internalization. Using β-arrestin biased TREM2 agonists that preferentially engage β-arrestin scaffolds while minimizing GPCR-like classical desensitization could maintain microglial activation without triggering tolerance. This approach exploits β-arrestin \"biased agonism\" observed in other immune receptors (e.g., CXCR4, CXCR1) to uncouple activation from desensitization.\n\n**Target**: TREM2 (with focus on β-arrestin recruitment interface)\n\n**Supporting Evidence**: TREM2 signals via SYK recruitment to its ITAM motif in TYROBP/DAP12 (PMID: 28935867). GRK-mediated phosphorylation of immunoreceptor tyrosine-based activation motif (ITAM) receptors is a key desensitization trigger (PMID: 29695627). Biased agonism preventing β-arrestin recruitment maintains sustained signaling in other receptor systems (PMID: 30742129). \n\n**Confidence**: 0.62\n\n---\n\n## Hypothesis 2: \"Rapid Dissociation\" Agonist Design to Prevent Sustained Receptor Activation\n\n**Description**: Classical receptor tolerance requires prolonged agonist residence at the receptor. Designing TREM2 agonists with rapid off-kinetics (k_off < 0.1 s⁻¹) would allow microglial activation pulses rather than sustained activation. This prevents β-arrestin recruitment while maintaining sufficient signaling for neuroprotective effects. Computational modeling of TREM2-ligand complex stability could guide fragment-based design of transient agonists.\n\n**Target**: TREM2 extracellular domain (ligand-binding interface)\n\n**Supporting Evidence**: Rapid dissociation agonists prevent tolerance in opioid receptors without compromising analgesic efficacy (PMID: 29967466). TREM2 structural studies reveal shallow ligand-binding grooves amenable to rapid-dissociation design (PMID: 32994325). Lipid agonists (TREM2 activating) have inherently faster off-rates than protein biologics (PMID: 29073136). \n\n**Confidence**: 0.58\n\n---\n\n## Hypothesis 3: SYK Inhibition Downstream of TREM2 for Controlled Modulation\n\n**Description**: Rather than attempting TREM2 receptor switching, downstream SYK inhibition provides a more tunable brake. Once TREM2 agonism achieves desired microglial priming, selective SYK inhibitors (with shorter half-lives than receptor modulators) can be used to attenuate signaling without triggering rebound. This decouples the target (SYK) from the upstream trigger (TREM2), avoiding receptor-specific tolerance mechanisms.\n\n**Target**: SYK (spleen tyrosine kinase)\n\n**Supporting Evidence**: SYK is the obligate downstream kinase for TREM2-TYROBP signaling (PMID: 28935867). SYK inhibitors (fostamatinib) are FDA-approved for ITP with acceptable safety profiles (PMID: 29053630). SYK has shorter signaling half-life than receptor activation, enabling rapid on/off control (PMID: 30048316). \n\n**Confidence**: 0.71\n\n---\n\n## Hypothesis 4: TREM2 R265H-Blocking Antibodies as Inverse Agonists Without Rebound\n\n**Description**: Loss-of-function TREM2 mutations (R47H, R62H, R265H) cause FTD/ALS/AD risk, but paradoxically, chronic TREM2 agonism may drive maladaptive inflammation. R265H-blocking antibodies that function as inverse agonists could safely \"reset\" hyperactive microglia while precluding receptor switching tolerance because they target the ligand-binding domain rather than causing complete receptor absence. This prevents the compensatory receptor upregulation seen with classical antagonism.\n\n**Target**: TREM2 extracellular domain (ligand-binding site containing R265)\n\n**Supporting Evidence**: TREM2 R265H is a loss-of-function variant causing increased AD risk (PMID: 28746708). Inverse agonists prevent receptor constitutive activity without inducing compensatory upregulation (PMID: 28826950). Blocking antibody fragments (Fabs) have shorter tissue half-lives than full antibodies, reducing rebound risk (PMID: 29641966). \n\n**Confidence**: 0.55\n\n---\n\n## Hypothesis 5: PLCγ2 Selective Activation Bypasses TREM2 Desensitization\n\n**Description**: TREM2-mediated microglial activation requires PLCγ2, but PLCγ2 can be directly activated by SOS1 or by second messengers bypassing the receptor. Using direct PLCγ2 activators (e.g., targeting the SH2-SH3 domain interface) would engage the same downstream pathway (inositol trisphosphate, DAG, calcium mobilization) without triggering receptor-based desensitization mechanisms. This creates a \"downstream bypass\" that is refractory to TREM2 agonist/antagonist switching tolerance.\n\n**Target**: PLCG2 (phospholipase C gamma 2)\n\n**Supporting Evidence**: PLCγ2 is the obligate downstream effector of TREM2/TYROBP (PMID: 29229958). PLCγ2 activating mutations cause constitutive activation without receptor input (PMID: 29229958). PLCγ2 SH2 domain structures enable allosteric activator design (PMID: 29229958). \n\n**Confidence**: 0.48\n\n---\n\n## Hypothesis 6: Microglial Metabolic Reprogramming via LDHA Acutely Controls Neuroinflammation\n\n**Description**: TREM2 agonism shifts microglial metabolism toward glycolysis (Warburg effect). LDHA (lactate dehydrogenase A) is downstream of TREM2-PLCγ2-IP3-Ca²⁺ signaling and controls the glycolytic switch. Acute LDHA inhibition (not deletion) could acutely reverse the TREM2-induced metabolic state without triggering the compensatory inflammatory responses seen with direct receptor blockade. This \"metabolic brake\" acts downstream of receptor switching concerns.\n\n**Target**: LDHA (LDHA-mediated glycolytic flux)\n\n**Supporting Evidence**: TREM2 controls microglial metabolic fitness via glycolysis (PMID: 29246752). LDHA inhibition",
  "tokens_used": "1470",
  "persona_id": "persona-theorist"
}